|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/24 GSK plc F-3ASR 3/25/24 12:25M Donnelley … Solutions/FA Glaxosmithkline Capital plc Glaxosmithkline Capital Inc. |
Document/Exhibit Description Pages Size
1: F-3ASR Automatic Shelf Registration Statement by a HTML 326K
Well-Known Foreign Issuer
2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 122K
3: EX-1.2 Underwriting Agreement or Conflict Minerals Report HTML 125K
4: EX-1.3 Underwriting Agreement or Conflict Minerals Report HTML 129K
5: EX-5.1 Opinion of Counsel re: Legality HTML 28K
6: EX-5.2 Opinion of Counsel re: Legality HTML 61K
7: EX-22 Published Report re: Matters Submitted to a Vote HTML 7K
of Security Holders
8: EX-23.3 Consent of Expert or Counsel HTML 7K
9: EX-25.1 Statement of Eligibility to Act as a Trustee HTML 500K
10: EX-25.2 Statement of Eligibility to Act as a Trustee HTML 500K
11: EX-25.3 Statement of Eligibility to Act as a Trustee HTML 500K
12: EX-FILING FEES Filing Fees HTML 66K
| EX-FILING FEES |
Exhibit 107
Calculation of Filing Fee Table
Form F-3
(Form Type)
GSK plc
GlaxoSmithKline Capital Inc.
GlaxoSmithKline Capital plc
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type |
Security Class Title |
Fee Calculation or Carry Forward Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit(1) |
Maximum Aggregate Offering Price(1) |
Fee Rate(1) |
Amount of Registration Fee(1) |
Carry Forward Form Type |
Carry Forward File Number |
Carry Forward Initial Effective date |
Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |||||||||||||
| Newly Registered Securities | ||||||||||||||||||||||||
| Fees to Be Paid |
Debt | Debt securities of GSK plc |
Rule 456(b) and Rule 457(r) | (2) | ||||||||||||||||||||
| Debt | Guaranteed debt securities of GlaxoSmithKline Capital plc |
Rule 456(b) and Rule 457(r) | (2) | |||||||||||||||||||||
| Debt | Guaranteed debt securities of GlaxoSmithKline Capital Inc. |
Rule 456(b) and Rule 457(r) | (2) | |||||||||||||||||||||
| Other | Guarantees of GSK plc in connection with guaranteed debt securities |
Rule 456(b) and Rule 457(r) | (3) | |||||||||||||||||||||
| Fees Previously Paid |
N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||||||||||
| Carry Forward Securities | ||||||||||||||||||||||||
| Carry Forward Securities |
Unallocated (Universal) Shelf |
Unallocated (Universal) Shelf |
Rule 415(a)(6) | (4) | $10,000,000,000 | F-3 | 333-254756, 333-254756-01 and 333-254756-02 | March 26, 2021 | $1,102,000 | |||||||||||||||
| Total Offering Amounts | Indeterminate | N/A | ||||||||||||||||||||||
| Total Fees Previously Paid | N/A | |||||||||||||||||||||||
| Total Fee Offsets | N/A | |||||||||||||||||||||||
| Net Fee Due | N/A | |||||||||||||||||||||||
Table 2: Fee Offset Claims and Sources
| Registrant Name |
Form or Filing Type |
File Number |
Initial Filing Date |
Filing Date |
Fee Offset Claimed |
Security Type Associated with Fee Offset Claimed |
Security Title Associated with Fee Offset Claimed |
Unsold Securities Associated with Fee Offset Claimed |
Unsold Aggregate Offering Amount Associated with Fee Offset Claimed |
Fee Paid with Fee Offset Source | ||||||||||||
| Rules 457(b) and 0-11(a)(2) | ||||||||||||||||||||||
| Fee Offset Claims | ||||||||||||||||||||||
| Fee Offset Sources | ||||||||||||||||||||||
| Rule 457(p) | ||||||||||||||||||||||
| Fee Offset Claims | ||||||||||||||||||||||
| Fee Offset Sources | ||||||||||||||||||||||
| (1) | An indeterminate aggregate initial offering price or number of the securities of each identified class is being registered as may from time to time be offered at indeterminate prices. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities. |
| (2) | In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), each Registrant is deferring payment of all of the registration fee. |
| (3) | Pursuant to Rule 457(n), no separate fee for the guarantees is payable. |
| (4) | Pursuant to Rule 415(a)(6) under the Securities Act, $10,000,000,000 of unsold securities (the “Unsold Securities”) previously registered on the Registration Statement on Form F-3 (File Nos. 333-254756, 333-254756-01 and 333-254756-02) filed on March 26, 2021, as amended by Post-Effective Amendment No. 1 filed on March 10, 2023 (such registration as amended, the “Prior Registration Statement”) are carried forward to this Registration Statement on Form F-3. The Registrants previously paid filing fees for the Unsold Securities in an aggregate amount of $1,102,000. Such aggregate amount of filing fees associated with the offering of the Unsold Securities is hereby carried forward to be applied to the Unsold Securities registered hereunder, and no additional filing fee is due with respect to the Unsold Securities in connection with the filing of this registration statement. Pursuant to Rule 415(a)(6), the offering of the Unsold Securities will be deemed terminated as of the effective date of this Registration Statement on Form F-3. |
| This ‘F-3ASR’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 3/25/24 | 6-K | ||
| 3/10/23 | 20-F, 6-K, IRANNOTICE, POS AM | |||
| 3/26/21 | F-3ASR | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/18 GSK plc 6-K 5/15/18 5:171K Donnelley … Solutions/FA 4/03/17 GSK plc F-3 17:1.7M Donnelley … Solutions/FA 3/18/13 GSK plc 6-K 3/18/13 5:511K Donnelley … Solutions/FA 3/04/08 GSK plc F-3ASR 3/04/08 13:1.5M Bowne - Bol/FA 4/07/04 Glaxosmithkline Capital Inc. 6-K 4/06/04 12:615K Donnelley … Solutions/FA |